Robert E. Funck Jr. - 17 Feb 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Robert E. Funck, Jr. by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
17 Feb 2023
Transactions value $
$0
Form type
4
Filing time
22 Feb 2023, 17:53:47 UTC
Previous filing
02 Mar 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +24.4K +11.82% $0.00 231K 17 Feb 2023 Direct F1
holding ABT Common shares without par value 10K 17 Feb 2023 By Trust F2
holding ABT Common shares without par value 10K 17 Feb 2023 By Trust F2
holding ABT Common shares without par value 18.4K 17 Feb 2023 Profit Sharing Trust F3
holding ABT Common shares without par value 500 17 Feb 2023 By Daughter F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +96.3K $0.00 96.3K 17 Feb 2023 Common Shares 96.3K $106.24 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
F3 Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.
F4 The reporting person disclaims beneficial ownership of all securities held by his daughter.
F5 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,100 on February 17, 2024, 32,100 on February 17, 2025, and 32,101 on February 17, 2026.